Founded in 2016, Arix Bioscience is a listed venture capital firm based in London, United Kingdom. The firm invests in seed-stage companies, preclinical and clinical-stage assets, private or public companies across biotech, healthcare and life science sectors.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
VelosBio | 02-Jul-2020 | Early Stage VC | 00000 | Drug Discovery | Clinical Trials - Phase 2 | 00000000 00000 00.0 |
00000000 | 08-May-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 000000 00000000 00.0 |
00000 | 01-Feb-2020 | 00000 00000 | 000.00 | Biotechnology | Clinical Trials - Phase 2 | 0000 0000 |
000000 000 | 27-Jan-2020 | 00000 00000 | 000.00 | Biotechnology | Startup | 00000000 00000 00.0 |
000000 | 09-Jan-2020 | 00000 00000 | 000.00 | Pharmaceuticals | Generating Revenue | 000000 00000000 00.0 |
00000 000000000000 | 30-Sep-2019 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000000 00000 00.0 |
0000 000 | 30-Apr-2019 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 00000000 00000 00.0 |
0000 00000000000 | 02-Apr-2019 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 0000 0000 |
Harpoon Therapeutics | 08-Feb-2019 | IPO | 0000 | Biotechnology | Generating Revenue/Not Profitable | 0000 0000 |
Aura Biosciences | 13-Dec-2018 | Later Stage VC | 000.00 | Biotechnology | Generating Revenue | 0000 0000 |
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
VelosBio | 18-Dec-2020 | Merger/Acquisition | 00.000 |
000000 00000000000 | 26-Oct-2020 | 000000 0000000000 | 000.00 |
00000 | 12-Mar-2020 | 000 | 000.00 |
0000000 | 22-Jan-2020 | 000000000 00000000 | |
0000000 | 11-Apr-2019 | 000000 0000000000 | 00000 |
0000000 0000000000 | 08-Feb-2019 | 000 | 0000 |
00000000 000000000 | 19-Oct-2018 | 000 | 0000 |
0000000 | 22-Jun-2018 | 000 | 00000 |
Iterum Therapeutics | 25-May-2018 | IPO | 0000 |
Verona Pharma | 26-Apr-2017 | Public Investment 2nd Offering | 0000 |
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialName | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Robert Lyne | Chief Operating Officer & General Counsel | London, United Kingdom | |||
Christian Schetter Ph.D | Managing Director | 0 | London, United Kingdom | ||
Jonathan Tobin Ph.D | Managing Director | 0 | 0 | 0 | London, United Kingdom |
John Cassidy Ph.D | Principal | 0 | London, United Kingdom | ||
Michelle Keating | Financial Controller | London, United Kingdom |
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
OrbiMed | 6 | 0 | 0 |
![]() |
![]() |
Lundbeckfond Ventures | 0 | 0 |
![]() |
![]() |
|
Cormorant Asset Management | 0 | 0 | 0 |
![]() |
![]() |
Sofinnova Investments | 0 | 0 | 0 |
![]() |
![]() |
Pappas Capital | 0 | 0 | 0 |
![]() |
![]() |